<DOC>
	<DOCNO>NCT00465400</DOCNO>
	<brief_summary>First , quantify , mean comet assay analysis , systemic oxidative stress patient non-exudative exudative age-related macular degeneration ( AMD ) compare result healthy control . Second , quantify systemic oxidative stress patient exudative AMD prior photodynamic ( PDT ) therapy .</brief_summary>
	<brief_title>Oxidative Stress Patients With Age-Related Macular Degeneration</brief_title>
	<detailed_description>Oxidative stress major factor play role pathogenesis age-related macular degeneration ( AMD ) , lead cause blind registration develop world . The term oxidative stress refers reversible damage molecule , example DNA , reactive form oxygen ( eg . free oxygen radical ) . This damage repair normally repair body . AMD classify two form : dry ( non-exudative ) wet ( exudative ) form . The exudative form AMD occur new blood vessel form improve blood supply retinal tissue . However , new blood vessel delicate break easily , cause bleed serious vision loss . The standardized method use treat exudative AMD photodynamic therapy ( PDT ) . This treatment base upon infusion drug activate light produce free radical destroy newly form vessel . In word , new vessel destroy iatrogenic source oxidative stress . This mean factor originally cause disease AMD , namely oxidative stress , finally use form treatment- destroy newly form blood vessel . In present study would like quantify first step level systemic oxidative stress patient non-exudative exudative AMD compare healthy control . In second step would like test whether treatment ( PDT ) patient exudative AMD additionally increase systemic oxidative stress . Oxidative stress quantify laboratory mean single cell gel electrophoresis comet assay .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>For patient dry non exudative AMD : Patients age 50 85 yr inclusive . Study eye must diagnosis nonexudative `` dry '' AMD â‰¥10 large soft , semisoft , and/or confluent drusen within 3,000 nm foveal center . Study eye must best correct visual acuity use ETDRS chart 0.1 patem 0.8 patem inclusive . Geographic atrophy allow long less 3 disc diameter within 3,000 nm foveal center . Study eye must condition limit view fundus . For patient exudative AMD clinical indication PDT treatment : Patients age 50 85 yr exudative AMD clinical indication PDT treatment . Primary recurrent subfoveal CNV due AMD Central 1mm retinal thickness ( optical coherence tomography ) &gt; 300 um Bestcorrected visual acuity , use ETDRS chart , &gt; 0.05patem Evidence recent disease progression , include loss least 1 line visual acuity macular hemorrhage within previous 12 wks . For healthy subject : An intraocular pressure &lt; 20 mmHg Normal blood pressure ( 100140/6090mm Hg ) Best correct visual acuity , use EDTRS chart 0.6 patem eye No pathological finding upon slitlamp examination indirect fundoscopy History ocular systemic disease History chronic current systemic topical medication , significant drug alcohol abuse ( significant define may influence result study History ocular trauma intraocular surgery within past 6 month History infection inflammation within past 3 month</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>exudative age-related macular degeneration ( AMD )</keyword>
	<keyword>non-exudative age-related macular degeneration ( AMD )</keyword>
	<keyword>oxidative stress</keyword>
	<keyword>photodynamic therapy</keyword>
</DOC>